Related Experiment Videos

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon

Robert Zivadinov1, Marino Zorzon, Maria Antonietta Tommasi

  • 1Department of Clinical Medicine and Neurology, Cattinara Hospital, University of Trieste, Strada di Fiume, 447-34149, Trieste, Italy.

Journal of the Neurological Sciences
|November 11, 2003
PubMed

Insights

One year of interferon beta-1a (IFNbeta-1a) treatment did not alter quality of life in relapsing-remitting multiple sclerosis (RRMS) patients. Mild side effects were reported but did not impact quality of life.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease.
  • Interferon beta-1a (IFNbeta-1a) is a common treatment for RRMS.
  • Understanding the long-term impact of IFNbeta-1a on patient well-being is crucial.

Purpose of the Study:

  • To evaluate the 12-month effect of interferon beta-1a (IFNbeta-1a) on quality of life (QOL) in RRMS patients.
  • To assess changes in disability, independence, cognition, mood, and fatigue.
  • To analyze the frequency and severity of IFNbeta-1a side effects and their correlation with QOL.

Main Methods:

  • A 12-month follow-up study involving 27 RRMS patients treated with IFNbeta-1a (Avonex).
  • Assessment of QOL, disability, independence, cognition, depression, anxiety, and fatigue at baseline, 6, and 12 months.
  • Weekly self-reported questionnaires on side effect frequency and severity post-injection.

Main Results:

  • Patient quality of life (QOL) showed no significant change over the 12-month follow-up period.
  • The percentage of patients reporting side effects remained constant, but the mean number of side effects increased significantly from month 6 to 12.
  • Mild side effects did not diminish over time, did not lead to treatment discontinuation, and did not correlate with QOL.
  • Disability progression was found to correlate with patient QOL.

Conclusions:

  • One-year treatment with interferon beta-1a (IFNbeta-1a) did not significantly alter patient quality of life in RRMS.
  • While side effects were persistent and increased over time, they were mild and did not negatively impact QOL or lead to treatment cessation.
  • Disability progression is a key factor influencing QOL in RRMS patients undergoing IFNbeta-1a therapy.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...